Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,516.27 98.74 0.68%
TOPIX 1,173.37 6.78 0.58%
HANG SENG 22,760.24 64.23 0.28%

Genzyme Receives Positive CHMP Opinion for LEMTRADA™ (alemtuzumab) in Europe


PR Newswire/Les Echos/

PRESS RELEASE


             Genzyme Receives Positive CHMP Opinion for LEMTRADA(TM)
                           (alemtuzumab) in Europe
     - CHMP also Recommends NAS Designation for AUBAGIO(r) (teriflunomide) 
                 Following Positive Opinion on Approval in March 2013 -
                 - Positive Opinions Set Stage for Introduction 
          of Two New Genzyme Therapies for Multiple Sclerosis in Europe -

Paris, France - June 28, 2013 - Sanofi (EURONEXT: SAN and NYSE: SNY) and its
subsidiary Genzyme announced today that the Committee for Medicinal Products 
for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a 
positive opinion for approval of LEMTRADA(TM) (alemtuzumab) for the treatment 
of adult patients with relapsing remitting multiple sclerosis (RRMS) with 
active disease defined by clinical or imaging features.

In addition, the CHMP issued a positive opinion on new active substance
designation (NAS) for AUBAGIO(r) (teriflunomide). Earlier this year, the CHMP
issued a positive opinion recommending the approval of AUBAGIO for the 
treatment of adult patients with relapsing remitting MS.

The European Commission (EC) is expected to render a final decision to grant
marketing authorizations for LEMTRADA and AUBAGIO in the EU in the coming
months.

"Today's CHMP opinions set the stage for the approval of two important new
treatment options for MS patients. Treatments to-date have addressed some of 
the unmet needs in MS, but still have limitations," said David Meeker, MD, 
Genzyme President and CEO. "Upon approval, physicians will have the ability to 
prescribe LEMTRADA for appropriate relapsing remitting patients based on their 
impressions of clinical or imaging characteristics regardless of duration of 
disease or treatment history. Expectations among the MS community are high for 
LEMTRADA and with today's positive CHMP opinion we are a step closer to making 
this very innovative treatment available for MS patients in Europe."

The positive CHMP opinion for approval of LEMTRADA was based on data from the
CARE-MS I and CARE-MS II trials, in which LEMTRADA was significantly more
effective than Rebif(r) (subcutaneous interferon beta-1a 44 mcg three times
weekly) at reducing relapse rates. In CARE-MS II, accumulation of disability 
was significantly slowed in patients given LEMTRADA vs. Rebif, and importantly,
patients treated with LEMTRADA were significantly more likely to experience
improvement in pre-existing disability.

"Today's announcement from Genzyme represents a key milestone in the extensive
program evaluating LEMTRADA in multiple sclerosis," said Professor Alastair
Compston, Head of the Department of Clinical Neurosciences at the University of
Cambridge, United Kingdom. "The superior efficacy of Lemtrada vs. Rebif in the
clinical trials, which was sustained despite infrequent administration,
represents an approach to treatment that promises to reshape the future for many
people with active relapsing-remitting multiple sclerosis."

LEMTRADA has a novel dosing and administration schedule of two annual treatment
courses. The first treatment course of LEMTRADA is administered via intravenous
infusion on five consecutive days, and the second course is administered on
three consecutive days, 12 months later.

The LEMTRADA clinical development program included two randomized Phase III
studies comparing treatment with LEMTRADA to Rebif in patients with
relapsing-remitting MS who had active disease and were either new to treatment
(CARE-MS I) or who had relapsed while on prior therapy (CARE-MS II), as well as
an ongoing extension study. A large randomized Phase II study provided the
foundation for the Phase III program.

Safety results were consistent across both the CARE-MS I and CARE-MS II studies.
The most common adverse events associated with LEMTRADA were infusion-associated
reactions, including headache, rash, fever, nausea and hives. Infections were
common in both the LEMTRADA and Rebif groups. Infections more common on LEMTRADA
treatment included upper respiratory and urinary tract infections, herpes viral
infections, and influenza. Most infusion-associated reactions and infections
were mild to moderate in severity and responded to standard treatments.

In both CARE-MS I and CARE-MS II, the incidence of serious adverse events was
similar between the two treatment arms. As previously reported, autoimmune
disorders were more frequent in patients treated with LEMTRADA, primarily
autoimmune thyroid disease which was observed in an estimated 36% of patients
during extended follow-up. Immune thrombocytopenia (ITP) developed in 1.4
percent of LEMTRADA-treated patients through extended follow-up and 0.3%
developed glomerulonephritis. Autoimmune disorders were detected soon after
onset through a monitoring program, and were generally managed using standard
treatments.

A comprehensive risk management program has been proposed to support early
detection and management of adverse events.

In the U.S. the FDA has accepted for review the company's supplemental 
Biologics License Application (sBLA) file seeking approval of LEMTRADA 
(alemtuzumab) for the treatment of relapsing multiple sclerosis (RMS). FDA 
recently extended the review cycle for LEMTRADA(TM) by three months; no 
additional clinical studies have been requested, therefore FDA action on the 
application is expected in late 2013.

About LEMTRADA(TM) (alemtuzumab)
Alemtuzumab is a monoclonal antibody that selectively targets CD52, a protein
abundant on T and B cells. Treatment with alemtuzumab results in the depletion
of circulating T and B cells thought to be responsible for the damaging
inflammatory process in MS. Alemtuzumab has minimal impact on other immune
cells. The acute anti-inflammatory effect of alemtuzumab is immediately 
followed by the onset of a distinctive pattern of T and B cell repopulation 
that continues over time, rebalancing the immune system in a way that 
potentially reduces MS disease activity.

Genzyme holds the worldwide rights to alemtuzumab and has primary 
responsibility for its development and commercialization in multiple sclerosis. 
Bayer HealthCare retains an option to co-promote alemtuzumab in multiple 
sclerosis. Bayer HealthCare has notified Genzyme of its intention to 
co-promote under this option. Upon regulatory approval and commercialization, 
Bayer would receive contingent payments based on sales revenue.

LEMTRADA is the proprietary name submitted to health authorities for the
company's investigational multiple sclerosis agent alemtuzumab.

About AUBAGIO(r) (teriflunomide)
AUBAGIO is an immunomodulator with anti-inflammatory properties. Although the
exact mechanism of action for AUBAGIO is not fully understood, it may involve a
reduction in the number of activated lymphocytes in the central nervous system
(CNS).

U.S. Indications and Usage

AUBAGIO (teriflunomide) is a once-daily, oral treatment indicated in the U.S.
for patients with relapsing forms of multiple sclerosis (MS). AUBAGIO 14 mg has
shown significant efficacy across key measures of MS disease activity, 
including reducing relapses, slowing the progression of physical disability, 
and reducing the number of brain lesions as detected by MRI. AUBAGIO 7mg has 
shown significant efficacy in reducing relapses and reducing the number of 
brain lesions as detected by MRI.

Important Safety Information About AUBAGIO

The AUBAGIO U.S. label includes a boxed warning citing the risk of
hepatotoxicity and, teratogenicity (based on animal data).

In MS clinical studies with AUBAGIO, the incidence of serious adverse events
were similar among AUBAGIO and placebo-treated patients. The most common 
adverse events associated with AUBAGIO in MS patients included increased ALT 
levels, alopecia, diarrhea, influenza, nausea and paresthesia. Teriflunomide 
is the principal active metabolite of leflunomide, which is indicated in the 
U.S. and Europe for the treatment of rheumatoid arthritis. Severe liver injury 
including fatal liver failure has been reported in patients treated with 
leflunomide.

Leflunomide has an estimated 2.1 million patient years of exposure in 
rheumatoid arthritis globally since its launch.

AUBAGIO is contraindicated in pregnant women and women of childbearing 
potential who are not using reliable contraception.

AUBAGIO is supported by a robust clinical program with more than 5,000 trial
participants in 36 countries and is amongst the largest of any MS therapy. Some
patients in extension trials have been treated for up to 10 years. The EU
AUBAGIO submission includes efficacy data from the TOWER (Teriflunomide Oral in
people With relapsing remitting multiplE scleRosis) and TEMSO (TEriflunomide
Multiple Sclerosis Oral) trials.

For full prescribing information and more information about AUBAGIO, please
visit www.genzyme.com.

About Genzyme, a Sanofi Company
Genzyme has pioneered the development and delivery of transformative therapies
for patients affected by rare and debilitating diseases for over 30 years. We
accomplish our goals through world-class research and with the compassion and
commitment of our employees. With a focus on rare diseases and multiple
sclerosis, we are dedicated to making a positive impact on the lives of the
patients and families we serve. That goal guides and inspires us every day.
Genzyme's portfolio of transformative therapies, which are marketed in 
countries around the world, represents groundbreaking and life-saving advances 
in medicine. As a Sanofi company, Genzyme benefits from the reach and resources 
of one of the world's largest pharmaceutical companies, with a shared 
commitment to improving the lives of patients. Learn more at 
www.genzyme.com.

Genzyme(r) is the reg istered trademark of Genzyme Corporation. All rights
reserved. 

Rebif(r) is a registered trademark of EMD Serono, Inc. or affiliates.

About Sanofi
Sanofi, an integrated global healthcare leader, discovers, develops and
distributes therapeutic solutions focused on patients' needs. Sanofi has core
strengths in the field of healthcare with seven growth platforms: diabetes
solutions, human vaccines, innovative drugs, consumer healthcare, emerging
markets, animal health and the new Genzyme. Sanofi is listed in Paris 
(EURONEXT: SAN) and in New York (NYSE: SNY).

About Bayer HealthCare
The Bayer Group is a global enterprise with core competencies in the fields of
health care, agriculture and high-tech materials. Bayer HealthCare, a subgroup
of Bayer AG with annual sales of EUR 18.6 billion (2012), is one of the world's
leading, innovative companies in the healthcare and medical products industry
and is based in Leverkusen, Germany. The company combines the global activities
of the Animal Health, Consumer Care, Medical Care and Pharmaceuticals 
divisions. Bayer HealthCare's aim is to discover, develop, manufacture and 
market products that will improve human and animal health worldwide. Bayer 
HealthCare has a global workforce of 55,300 employees (Dec 31, 2012) and is 
represented in more than 100 countries. More information at 
www.healthcare.bayer.com.

Sanofi Forward Looking Statements
This press release contains forward-looking statements as defined in the 
Private Securities Litigation Reform Act of 1995, as amended. Forward-looking 
statements are statements that are not historical facts. These statements 
include projections and estimates and their underlying assumptions, statements 
regarding plans, objectives, intentions and expectations with respect to 
future financial results, events, operations, services, product development 
and potential, and statements regarding future performance. Forward-looking 
statements are generally identified by the words "expects", "anticipates", 
"believes", "intends", "estimates", "plans" and similar expressions. Although 
Sanofi's management believes that the expectations reflected in such 
forward-looking statements are reasonable, investors are cautioned that 
forward-looking information and statements are subject to various risks and 
uncertainties, many of which are difficult to predict and generally beyond the 
control of Sanofi, that could cause actual results and developments to differ 
materially from those expressed in, or implied or projected by, the 
forward-looking information and statements. These risks and uncertainties 
include among other things, the uncertainties inherent in research and 
development, future clinical data and analysis, including post marketing, 
decisions by regulatory authorities, such as the FDA or the EMA, regarding 
whether and when to approve any drug, device or biological application that may
be filed for any such product candidates as well as their decisions regarding 
labelling and other matters that could affect the availability or commercial 
potential of such product candidates, the absence of guarantee that the 
product candidates if approved will be commercially successful, the future 
approval and commercial success of therapeutic alternatives, the Group's 
ability to benefit from external growth opportunities, trends in exchange 
rates and prevailing interest rates, the impact of cost containment policies 
and subsequent changes thereto, the average number of shares outstanding as 
well as those discussed or identified in the public filings with the SEC and 
the AMF made by Sanofi, including those listed under "Risk Factors" and 
"Cautionary Statement Regarding Forward-Looking Statements" in Sanofi's annual 
report on Form 20-F for the year ended December 31, 2012. Other than as 
required by applicable law, Sanofi does not undertake any obligation to update 
or revise any 
forward-looking information or statements.

Contacts:

Sanofi Media Relations             Sanofi Investor Relations
Marisol Péron                      Sébastien Martel
Tel: +33 (0) 1 53 77 46 46         Tel: +33 (0) 1 53 77 45 45
E-mail: mr@sanofi.com              E-mail: ir@sanofi.com 

Genzyme Media Relations            Sanofi Investor Relations
Erin Walsh                         Kristen Galfetti
Tel: 617-768-6881                  Tel: +1 908 981 5560
E-mail: Erin.Walsh@genzyme.com     E-mail: ir@sanofi.com

The content and accuracy of news releases published on this site and/or distributed by PR Newswire or its partners are the sole responsibility of the originating company or organisation. Whilst every effort is made to ensure the accuracy of our services, such releases are not actively monitored or reviewed by PR Newswire or its partners and under no circumstances shall PR Newswire or its partners be liable for any loss or damage resulting from the use of such information. All information should be checked prior to publication.

-0- Jun/28/2013 13:21 GMT

Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement